483
National Cancer Institute, Cancer Therapy Evaluation ProgramNational Cancer Institute, Cancer Therapy Evaluation Program – FDA 483, Jul 17, 2014
Record Details
The FDA inspected the National Cancer Institute, Cancer Therapy Evaluation Program, revealing significant deficiencies in the oversight of clinical investigations. Observations included failures to ensure investigator qualifications, adequately monitor study progress, obtain complete FDA-1572 statements, and collect required financial disclosure information from investigators. These issues indicate a lack of adherence to regulatory requirements for clinical trial conduct.
- Inspection date
- July 17, 2014
- Product type
- drugs
View Company Profile
ID · df2145ec-53be-4693-bace-5d10a2c865b2
Other documents for National Cancer Institute, Cancer Therapy Evaluation Program
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.